Compare EHTH & SCYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EHTH | SCYX |
|---|---|---|
| Founded | 1997 | 1999 |
| Country | United States | United States |
| Employees | N/A | 29 |
| Industry | Specialty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 52.4M | 42.4M |
| IPO Year | 2006 | 2014 |
| Metric | EHTH | SCYX |
|---|---|---|
| Price | $1.42 | $4.00 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | ★ $3.33 | $3.00 |
| AVG Volume (30 Days) | ★ 529.1K | 94.2K |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 71.43 | 61.36 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $251,395,000.00 | $257,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $5.60 | $608.78 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 45.86 | N/A |
| 52 Week Low | $1.20 | $0.57 |
| 52 Week High | $5.89 | $5.62 |
| Indicator | EHTH | SCYX |
|---|---|---|
| Relative Strength Index (RSI) | 38.78 | 47.27 |
| Support Level | $1.43 | $3.68 |
| Resistance Level | $1.58 | $5.62 |
| Average True Range (ATR) | 0.13 | 0.39 |
| MACD | -0.02 | -0.12 |
| Stochastic Oscillator | 2.63 | 4.47 |
eHealth Inc is a company involved in private health insurance marketplace with a technology and service platform that provides consumer engagement, education and health insurance enrollment solutions. The company operates its business in two segments: Medicare which provides health insurance plans and lesser extent ancillary products such as dental and vision insurance and hospital indemnity plans, to medicare eligible consumers; and Employer and Individual provides individual and family health insurance, and small business health insurance plans and Individual Coverage Health Reimbursement Arrangements. It derives maximum revenue from Medicare Segment. All of the company's revenue is derived from the United States. It also has a presence in China.
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.